Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Nektar Therapeutics (NKTR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, scheduled for May 20, 2025, at the Nasdaq Headquarters in New York City. The company will host a fireside chat that will be webcast starting at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. The presentation will be accessible through a webcast link and on Nektar's investor relations website, with a replay available for 30 days. Interested parties seeking one-on-one meetings with management should contact their H.C. Wainwright representative.
Nektar Therapeutics (NKTR) ha annunciato la sua partecipazione al 3° Annuale BioConnect Investor Conference di H.C. Wainwright, previsto per il 20 maggio 2025, presso la sede del Nasdaq a New York City. L'azienda terrà una chiacchierata informale trasmessa in webcast a partire dalle 13:30 ora Eastern / 10:30 ora Pacific. La presentazione sarà disponibile tramite un link webcast e sul sito web delle relazioni con gli investitori di Nektar, con una replica accessibile per 30 giorni. Chi fosse interessato a incontri individuali con il management è invitato a contattare il proprio rappresentante H.C. Wainwright.
Nektar Therapeutics (NKTR) ha anunciado su participación en la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright, programada para el 20 de mayo de 2025, en la sede de Nasdaq en Nueva York. La compañía realizará una charla informal que será transmitida por webcast a partir de las 1:30 p.m. hora del Este / 10:30 a.m. hora del Pacífico. La presentación estará disponible a través de un enlace de webcast y en el sitio web de relaciones con inversores de Nektar, con una repetición disponible durante 30 días. Las personas interesadas en reuniones individuales con la dirección deben contactar a su representante de H.C. Wainwright.
Nektar Therapeutics (NKTR)는 2025년 5월 20일 뉴욕 나스닥 본사에서 예정된 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참가한다고 발표했습니다. 회사는 동부 시간 오후 1시 30분 / 태평양 시간 오전 10시 30분부터 웹캐스트로 진행되는 비공식 대화를 주최할 예정입니다. 발표는 웹캐스트 링크와 Nektar 투자자 관계 웹사이트를 통해 접속할 수 있으며, 30일 동안 재시청이 가능합니다. 경영진과의 일대일 미팅을 원하는 분들은 H.C. Wainwright 담당자에게 연락하시기 바랍니다.
Nektar Therapeutics (NKTR) a annoncé sa participation à la 3e conférence annuelle BioConnect pour investisseurs d'H.C. Wainwright, prévue le 20 mai 2025 au siège du Nasdaq à New York. La société animera une discussion informelle diffusée en webcast à partir de 13h30 heure de l'Est / 10h30 heure du Pacifique. La présentation sera accessible via un lien webcast et sur le site des relations investisseurs de Nektar, avec une rediffusion disponible pendant 30 jours. Les personnes souhaitant organiser des réunions individuelles avec la direction sont invitées à contacter leur représentant H.C. Wainwright.
Nektar Therapeutics (NKTR) hat seine Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright angekündigt, die am 20. Mai 2025 im Nasdaq-Hauptquartier in New York City stattfinden wird. Das Unternehmen wird ein informelles Gespräch veranstalten, das ab 13:30 Uhr Eastern Time / 10:30 Uhr Pacific Time per Webcast übertragen wird. Die Präsentation ist über einen Webcast-Link und auf der Investor-Relations-Website von Nektar zugänglich, mit einer Wiederholung, die für 30 Tage verfügbar ist. Interessenten, die Einzelgespräche mit dem Management wünschen, sollten ihren H.C. Wainwright-Ansprechpartner kontaktieren.
- None.
- None.
- H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025 – webcast to be available at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time – link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contact:
For Investors:
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-hc-wainwright-3rd-annual-bioconnect-investor-conference-302454157.html
SOURCE Nektar Therapeutics
FAQ
When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright BioConnect Conference 2025?
Where can I watch Nektar Therapeutics' (NKTR) H.C. Wainwright conference presentation?
How can investors arrange meetings with Nektar Therapeutics (NKTR) management at the conference?
Where is the H.C. Wainwright BioConnect Conference 2025 being held?
